Beta Bionics Inc. demonstrated strong growth in Q4 2025, with net sales increasing by 57% to $32.1 million, driven by significant expansion in the Pharmacy Benefit Plan channel. The company also saw a substantial increase in its installed customer base and new patient starts, while improving its gross margin.